Screener
TG Therapeutics TGTX Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent.
The source filing: TG Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:01 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025955
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Total assets | $1,639,629 | $1,063,253 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | $213,693 | $107,508 |
| Other current liabilities | 857 | 2,124 |
| Lease liability – current portion | 1,913 | 1,044 |
| Deferred revenue - current portion | 16,825 | 21,234 |
| Accrued compensation | 35,205 | 21,850 |
Document
FAQ
- What is TG Therapeutics's accounts payable?
- TG Therapeutics (TGTX) reported accounts payable of $213.69M in Q2 2026.
- How has TG Therapeutics's accounts payable changed year-over-year?
- TG Therapeutics's accounts payable increased by 59.4% year-over-year, from $134.02M to $213.69M.
- What is the long-term trend for TG Therapeutics's accounts payable?
- Over 5 years (2020 to 2025), TG Therapeutics's accounts payable has grown at a 23.8% compound annual growth rate (CAGR), from $37.01M to $107.51M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about TG Therapeutics's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude